Macrogenics (MGNX) Cash from Financing Activities (2012 - 2026)
Macrogenics (MGNX) posted quarterly Cash from Financing Activities of -$207000.0 for Q1 2026, up 26.6% year-over-year from -$163512.6 in Q1 2025, and down 463.16% quarter-over-quarter from $57000.0 in Q4 2025.
Powered by 
Analysis
Macrogenics (MGNX) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Cash from Financing Activities for 15 consecutive years, with -$207000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 26.6% year-over-year to -$207000.0; the TTM figure through Mar 2026 stood at $69.6 million (up 16083.49% YoY), while the FY2025 annual figure was $69.5 million, up 7141.04% from the prior year.
- Cash from Financing Activities fell to -$207000.0 in Q1 2026 per MGNX's latest filing, from $57000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $100.1 million in Q1 2023 and bottomed at -$282000.0 in Q1 2025.
- Historically, Cash from Financing Activities has averaged $14.8 million across 5 years, with a median of $248000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 270489.19% — and 2025, when it tumbled 213.71%.
- Macrogenics' Cash from Financing Activities stood at $1.4 million in 2022, then plunged by 79.91% to $273000.0 in 2023, then sank by 43.22% to $155000.0 in 2024, then tumbled by 63.23% to $57000.0 in 2025, then tumbled by 463.16% to -$207000.0 in 2026.
- Business Quant data shows MGNX's Cash from Financing Activities at -$207000.0 in Q1 2026, $57000.0 in Q4 2025, and $69.7 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - | 60.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 60.17 Mn |
| Mar 31, 2026 | -207,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Jun 30, 2025 | 69.74 Mn |
| Mar 31, 2025 | -282,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Sep 30, 2023 | 49.91 Mn |
| Jun 30, 2023 | 59,000.00 |
| Mar 31, 2023 | 100.12 Mn |
| Dec 31, 2022 | 1.36 Mn |
| Jun 30, 2022 | 263,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Dec 31, 2021 | 800,000.00 |
| Sep 30, 2021 | 18.97 Mn |
| Jun 30, 2021 | 2.35 Mn |
| Mar 31, 2021 | 100.66 Mn |